Actively Recruiting
Characterizing High-Risk Non-Muscle-Invasive Bladder Cancer Diagnosis and Care A Retrospective Study in Portugal
Led by Janssen-Cilag Farmaceutica Ltda. · Updated on 2026-08-28
250
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying people with high-risk non-muscle invasive bladder cancer HR-NMIBC in Portugal to understand how they are diagnosed, treated, and cared for in normal clinical settings. HR-NMIBC is an early form of bladder cancer limited to the bladders inner lining but has a high chance of recurring or worsening. This study collects information retrospectively from participants diagnosed between 2016 and 2020. Participants diagnosed with HR-NMIBC will have their demographic and clinical data gathered from medical records, including electronic and paper files, covering the time from diagnosis up to at least five years afterward. This study does not involve giving any drugs or treatments but focuses on observing routine clinical practice and treatment patterns over time. During the study, researchers will review records for treatment types, surgeries performed, and therapy details by tumor stage and histology. They will also assess outcomes such as recurrence-free survival, progression-free survival, overall survival, and healthcare resource use over a five-year period. No active intervention is given, and the study duration depends on data collected from past routine care.
CONDITIONS
Brief Title
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here